"10.1371_journal.pone.0058752","plos one","2013-03-15T00:00:00Z","Anna M Lilja; Jennie Röjdner; Tamanna Mustafiz; Carina M Thomé; Elisa Storelli; Daniel Gonzalez; Christina Unger-Lithner; Nigel H Greig; Agneta Nordberg; Amelia Marutle","Alzheimer Neurobiology Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden; Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden; Drug Design & Development Section, Laboratory of Neurosciences, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, United States of America","Conceived and designed the experiments: AML AM. Performed the experiments: AML JR TM CMT ES DG CUL AM. Analyzed the data: AML JR TM ES CUL AM. Contributed reagents/materials/analysis tools: NHG. Wrote the paper: AML JR NHG AN AM.","Agneta Nordberg is PI for clinical trials sponsored by Torrey pines Therapeutics, GSK, Wyeth, and has been a consultant for AstraZeneca, served on the advisory board for Elan, Pfizer, GSK, Novartis, Lundbeck AB, GE Health Care, and received honorarium for lectures from Novartis, Jansen-Cilag, Pfizer, Merck and received research grants from Novartis, Pfizer, GE Healthcare, Johnson & Johnson. The experimental Alzheimer drugs, (−)-phenserine and (+)-phenserine, both derive from Nigel H. Greig’s research and are covered in patents that have been assigned to the National Institutes of Health and Dr. Greig has no ownership of these patents. None of the other authors have any conflicts of interest and potential competing interests. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.","2013","03","Anna M Lilja","AML",10,TRUE,2,8,6,5,TRUE,TRUE,FALSE,0,NA,FALSE
